Skip to main content

Table 2 Findings from usual care and intervention

From: Improving diagnostics using extended point-of-care testing during in-home assessments of older adults with signs of emerging acute disease: a prospective observational non-randomised pilot and feasibility study

 

Total study sample (N = 100)

Usual care - ACNs in-home assessment

Vital signs

  Respiratory rate, breaths/min

   Median (IQR)

21(18–24)

   Range

11–50

  Saturation, %

   Median (IQR)

96(92–99)

   Range

77–100

  Systolic blood pressure, mmHg

   Median (IQR)

133 (117–143)

   Range

81–208

  Diastolic blood pressure, mmHg

   Median (IQR)

74 (67–80)

   Range

49–113

  Heart rate, beats/min

   Median (IQR)

81 (71–92)

   Range

44–116

  Body temperature

   Median (IQR)

36.9 (36.6–37.4)

   Range

35.7–40

  GCS

   Median (IQR)

15 (15–15)

Simple POCT

  C-Reactive protein, mg/L

   Median (IQR)

24 (5.3–57)

   Range

0.6–171

  Haemoglobin, mmol/L

   Median (IQR)

7.4 (6.6–8.1)

   Range

0.1–10.2

Presumptive diagnoses, made by the acute nurse, n

  Pneumonia

20

  Viral infection

18

  Urine infection

5

  Infection, unclear focus

6

  AE-COPDb

15

  Otherc

36

Intervention – Results from Extended POCT

Feasibility of extended POCT, n

  FLUS

100

  Creatinine, electrolytes, leucocytes with differential count

89

  PCR for upper respiratory pathogens

79

  Urine flow cytometry

4

FLUS, n

100

  Patient positioning

   8 scanning zones

28

   14 scanning zones

72

  Normal

36

  Pneumothorax

≤ 3a

  Interstitial syndrome

8

  Pleural Effusion

32

   Unilateral

25

   Bilateral

≤ 3a

   Simple

30

   Complex

≤ 3a

   Small

26

   Moderate

3

   Large

3

Pneumonia, n

25

  Consolidated lung tissue

≤ 3a

  Dynamic bronchoaerograms

≤ 3a

  Focal B-lines

7

  Focal B-lines, fragmented and thickened visceral pleura, and pleural effusion

15

Other pathologies, n

16

  Thickened parietal pleura

7

  Uncharacteristic lung consolidations

6

  Tumour/suspected malignancy

3

Venous blood samples, n

89

  Creatinine, µmol/L

   Median (IQR)

80 (66–118)

   Range

24–281

  Na+, mmol/L

   Median (IQR)

138 (136–140)

   Range

126–144

  K+, mmol/L

   Median (IQR)

4 (3.7–4.2)

   Range

3.2–5.3

  Blood Urea Nitrogen (BUN), mmol/L

   Median (IQR)

7.7 (6.2–10.5)

   Range

1.8–26.5

  Total leucocytes, 109/L

   Median (IQR)

9.4 (7.3–12,1)

   Range

1.6–25

  Neutrophils, 109/L

   Median (IQR)

5.1 (3.9–7.7)

   Range

0.3–19

  Lymphocytes, 109/L

   Median (IQR)

2.3 (1.8–2.8)

   Range

0.8–5.2

  Monocytes, 109/L

   Median (IQR)

0.6 (0.4–0.7)

   Range

0–1.6

  Eosinophils, 109/L

   Median (IQR)

0.3 (0.2–0.6)

   Range

0–4

  Basophils, 109/L

   Median (IQR)

0 (0–0.1)

   Range

0–0.9

Biofire filmarray, n

79

  Respiratory pathogens detected

≤ 3a

Urine samples, n

4

  > 105 BACT/ml

≤ 3a

Primary care physician contact

Primary care Physician, n

  Doctor reached by phone,

61

  Secretary reached by phone

17

  No phone contact

22

Initiated treatment during in-home-assessments, n

48

  Antibiotic, oral, no (%)

18 (37)

  Diuretics, oral, no (%)

3 (6)

  Acute hospital admission following in-home assessments, no (%)

21 (43)

  Other treatmentsd, no (%)

12 (25)

Planned follow-up in-home assessment by ACN

  Planned new in-home assessment in 3 days

15

  1. Abbreviations: ACN Acute Community Nurse, FLUS Focused Lung Ultrasound, POCT Point-of-care Testing
  2. aDue to Danish Legislation and EU General Data Protection Agency reporting of observations below 3 is not permitted
  3. bAE-COPD Acute exacerbation of chronic obstructive pulmonary disease
  4. cOther: suspected malignancy (6), functional decline (4), chronic condition (10), orthostatic hypotension (4), dehydration (≤ 3), heart problem (≤ 3), skin infection (≤ 3), deep venous thrombosis (≤ 3), not ill (≤ 3), anaemia (≤ 3), unclear but ill (≤ 3)
  5. dOther treatments: Salbutamol inhalation (3), prednisolone (3), increased home care (3), subcutaneous furosemide injection (≤ 3), cutaneous antibiotic (≤ 3), change in antibiotics (≤ 3)